GT Biopharma shares surge 30.09% intraday as Phase 1 trial advances and GTB-5550 IND submission looms.

GT Biopharma surged 30.09% intraday following the release of its Q3 2025 financial results and corporate update. The company highlighted progress in its Phase 1 trial of GTB-3650 for hematologic malignancies, which advanced to Cohort 4 at 10 µg/kg/day, with the next update expected in Q1 2026. It also announced plans to submit an IND application for GTB-5550 targeting B7H3-expressing solid tumors by late December 2025 or January 2026. Reduced R&D expenses ($0.6M vs. $1.3M in Q3 2024) and a $2.6M cash balance sufficient to fund operations into early 2026 were cited as operational improvements. Management emphasized GTB-3650’s safety profile and potential competitive advantages in immuno-oncology, fueling investor optimism about near-term clinical and regulatory milestones.